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Abstract
Cord blood hematopoietic progenitor cells (CB-HPCs) transplanted immunodeficient NOD/LtsZ-scidIL2Rc
null (NSG) and
NOD/SCID/IL2Rc
null (NOG) mice need efficient human cell engraftment for long-term HIV-1 replication studies. Total body
irradiation (TBI) is a classical myeloablation regimen used to improve engraftment levels of human cells in these humanized
mice. Some recent reports suggest the use of busulfan as a myeloablation regimen to transplant HPCs in neonatal and adult
NSG mice. In the present study, we further ameliorated the busulfan myeloablation regimen with fresh CB-CD34+cell
transplantation in 3–4 week old NSG mice. In this CB-CD34+transplanted NSG mice engraftment efficiency of human
CD45+cell is over 90% in peripheral blood. Optimal engraftment promoted early and increased CD3+T cell levels, with
better lymphoid tissue development and prolonged human cell chimerism over 300 days. These humanized NSG mice have
shown long-lasting viremia after HIV-1JRCSF and HIV-1Bal inoculation through intravenous and rectal routes. We also saw a
gradual decline of the CD4+T cell count, widespread immune activation, up-regulation of inflammation marker and
microbial translocation after HIV-1 infection. Humanized NSG mice reconstituted according to our new protocol produced,
moderate cellular and humoral immune responses to HIV-1 postinfection. We believe that NSG mice reconstituted
according to our easy to use protocol will provide a better in vivo model for HIV-1 replication and anti-HIV-1 therapy trials.
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Introduction
In recent years, efforts have been made to reconstitute a
functional human immune system in murine models [1,2].
Multilineage differentiation and self-renewal capacity of CD34
+
cells have been explored to reconstitute various kind of immuno-
deficient mice [3,4,5,6,7]. Third generation, NOD-Rag1nul-
lIL2Rc
null, NOD/LtSz-scid/IL2Rc
null (NSG) and NOD/SCID/
IL2Rc
null (NOG) mice lack common interleukin-2 receptor
gamma chain (IL2Rc). IL2Rc chain deficiency inhibits natural
killer cell differentiation and causes defects in innate immunity [8].
When transplanted with human HPCs after low-dose TBI, these
strains of mice display higher levels of engraftment compared to
what has been previously obtained with other immunodeficient
mouse stocks [5,7,9,10]. Satisfactory levels of human cell
engraftment have usually been achieved after TBI conditioning
and CD34
+ cell transplantation in newborn or 8–9 week old mice
[2,3,4,5,6,7]. These humanized NSG and NOG mouse models
have allowed sufficient levels of human cell chimerism and are
suitable for HIV-1 infection studies [5,7,11].
Nevertheless, there is still room for improvingthe differentiation
of lymphoid tissues in the reconstituted mice and reaching T cell
counts sufficient to sustain long-term HIV replication. It is also of
paramount importance to reproduce in such models the different
types of non-specific and specific immune responses associated
with HIV infection and influencing its prognosis (i.e. immune
activation, immune senescence, immune exhaustion and specific
anti-HIV responses).
It has been shown that myelosuppression generated by busulfan
(1,4-Butanedioldimethanesulfonate) improves CD45
+ cell engraft-
ment in humanized NSG mice. An initial protocol used busulfan
conditioning at 50 mg/kg and transplantation of 2610
6 CB-HPCs
along with a cytokine cocktail for humanization of NSG mice [12].
However, in another study, busulfan at 40 mg/kg was lethal for
NSG mice [13]. Neonatal NSG mice have also been pretreated
with 15 mg/kg busulfan and transplanted following various
protocols involving intrahepatic or facial vein injection of CD34
+
cells [14,15]. However, such technical procedures performed in
neonatal mice remain delicate and require expertise.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38491In the present study, we further optimized the busulfan
conditioning protocol by transplanting fresh CB-HPCs through
tail vein injection in 3–4 week old NSG mice after 50 mg/kg
busulfan treatment. This protocol allowed to improve human cell
engraftment and to reach T cell levels that can support intense and
prolonged HIV replication in NSG mice. It also permitted
differentiation of human monocytes and dendritic cells (DCs) and
improved the development of lymphoid structures such as lymph
nodes and thymus. Overall, the survival of engrafted mice was
lengthened. Interestingly, infected mice developed specific humor-
al and cell-mediated immune responses as well as signs of non-
specific immune activation and senescence. This improved
protocol provides an easy and suitable model for the study of
HIV pathogenesis and the evaluation of new therapeutic
approaches.
Materials and Methods
Mice
NOD/LtSz-scid/IL2Rc
null (NSG) mice were purchased from
Jackson Laboratory (Bar Harbor, Maine, USA). Mice were bred
and kept in a specific pathogen-free animal facility of the GIGA-
Research of University of Lie `ge (Lie `ge, Belgium). Mice were
maintained in micro-isolator cages and fed with autoclaved food
and water. The females as well as male mice were used in all the
experiments. Animal handling was in agreement with national
legislation and institutional guidelines. University of Liege ethical
committee has approved the use of mice, ethical application
approval number-670.
Pretransplantation Conditioning and Transplantation of
Human Cord Blood-Derived Hematopoietic Stem Cells in
NSG Mice
Busulfan (Sigma Aldrich, Munich, Germany) was dissolved in
DMSO and diluted with RPMI-1640. Busulfan 20 mg/kg or
30 mg/kg was administered by a single intraperitoneal injection.
For higher doses (i.e. 50–60 mg/kg), the administration was split in
two i.p. injections with a 12-hour delay. Human cord blood (CB)
was provided by the cord blood bank of the University Hospital,
Liege, Belgium. CB mononuclear cells were separated by Ficoll-
Hypaque density gradient. CD34
+ cells were positively selected by
magnetic separation using a direct CD34
+ cell isolation kit (Stem
Cells Technologies, Grenoble, France) according to the manufac-
turer’s instruction. Sorted cells always had purity over 95%, when
checked by flow cytometry. Cells were either immediately used for
the transplantation or frozen in liquid nitrogen until further use.
We transplanted 1 to 2610
5 frozen or 2610
5 fresh CD34
+ cells by
i.v. tail injection.
Flow Cytometry
Peripheral blood was taken from the tail vein at different times
after transplantation of CD34
+ cells. Red blood cells lysis was
performed before labeling with specific antibodies and immune
phenotyping with BD FACS Canto II flow cytometry (BD
Biosciences, Erembodegem, Belgium). Mice were sacrificed by
cervical dislocation at specific time points to evaluate engraftment
of human cells in different lymphoid organs of the CD34
+
transplantedanimals. Lymph nodes, spleen, bone marrow and
thymus were dissociated with syringes to obtain single-cell
suspensions and passed through a nylon cell strainer, washed
three times with RPMI-1640, labeled with antibodies and
analyzed for the presence of different human cell populations.
Antibodies used were allophycocyanin conjugated anti–human
CD45, fluoresceinisothiocyanate (FITC) conjugated anti-mouse
CD45, anti–human CD4, anti-human granzymeB, anti-human
CD11c, phycoerythrin (PE) conjugated anti–human CD3, anti-
human CD69, anti-human HLA-DR, anti-human PD-1, anti-
human CD27, anti-human perforin, peridinin chlorophyll protein
conjugated (PerCP) anti–human CD8 and anti-human CD14. All
antibodies were purchased from BD Biosciences (Erembodegem-
Aalst, Belgium). We also used anti-human CXCR4-PE and anti-
human CCR5-PE from RD Systems (Oxon, United Kingdom).
In some experiments, white blood cells were numerated using a
Cell-Dyn 3700 analyzer (Abbott, Wiesbaden, Germany) with
human settings.
Immunohistochemistry
Immunohistochemistry was performed on tissue sections from
thymus, spleen, and lymph nodes of humanized NSG mice.
Sections were fixed with 4% paraformaldehyde and dehydrated
with graded alcohol. After treatment with heated citrate buffer for
antigen retrieval, sections were blocked for endogenous peroxidase
activity. Following this, sections were incubated in 10% goat
serum and then with primary antibodies at 4uC overnight. Fixed
samples were stained with the following antibodies, anti–human
CD45 (MS355P, Neomarkers), CD3 (ab828, abcam), CD20 (L26;
M0755, DAKO), CD138 (MCA681H, Serotec), Ki67 (MIB1;
M7240, DAKO), and HIV-1 Gag p24 (DAKO) for detection of
infected cells. After incubation for 30 minutes with the secondary
antibody, the specimens were visualized by DAB treatment.
Sections were lightly counterstained with hematoxylin to enable
visualization of nuclei. Stained specimens were observed by using
transmitted light microscopy (Olympus BX 40, Aartselaar,
Belgium).
Proliferative Responses of Lymph Node and Spleen T-
Cells Ex Vivo
Single-cell suspensions of mononucleated cells were prepared
from the spleens and lymph nodes of mice after 22 weeks of
CD34
+ cell transplantation. PBMCs from healthy human donors
were also isolated by centrifugation over Ficoll-Hypaque (Lym-
phoprep; Nycomed, Birmingham, United Kingdom). Cells were
washed in RPMI-1640 after treatment with erythrocyte lysis buffer
and then suspended in RPMI-1640 complete medium supple-
mented with 10% (v/v) heat-inactivated FBS. These cells were
cultured at 1610
6/ml (100 ml/well), at 37uC in a 5% CO2 and
humid atmosphere in round-bottom 96-well microtiter plates
(Costar, Kruibeke, Belgium), with medium alone or with the
combination of immobilized CD3 (10 mg/ml) (145-2C11, BD
Biosciences) and anti-CD28 (1 mg/ml) (CD28.2, BD Biosciences)
or anti-CD3 (10 mg/ml) and recombinant IL2 (50 U/ml) (Roche,
Vilvoorde, Belgium). After culture cells for 68 h, cells were pulsed
with 0.4 mCi/well
3H thymidine and incubated for an additional
4 h before harvesting. Cells were harvested onto glass fiber filters
(Filter Mate, PerkinElmer, Zaventem, Belgium), and radioactivity
was quantified using TopCountH NXT
TM Microplate Scintillation
and Luminescence Counter (PerkinElmer, Zaventem, Belgium).
Samples were assayed in triplicate. The data are presented as
mean cpm6standard deviation (SD).
Virus Culture
The HIV-1JRCSF and HIV-1Bal were obtained from the NIH-
AIDS Research and Reference Reagent Program. PBMCs were
isolated from HIV-1 seronegative individuals and cultured in
RPMI-1640 supplemented with 10% FBS and antibiotics with
5 mg/ml of phytohemagglutinin for 3–4 days (PHA-PBMCs). Cells
were then mixed with the virus and cultured for seven days in
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antibiotics. The endpoints were determined by screening for the
p24 antigen using ELISA (Innogenetics NV, Ghent, Belgium).
HIV-1 Infection
Infection and maintenance of humanized NSG mice were
performed in GIGA-R-Biosafety Level 3 facilities under standard
caging conditions. 130 to 155 days post CB-CD34
+ cell
transplantation, two groups of seven mice each were inoculated
i.v. with HIV-1JRCSF (10,000 TCID50) and HIV-1Bal (10,000
TCID50). Plasma from infected mice were collected six times at
20-day intervals to determine HIV-RNA copy number. Blood cells
were prepared after RBC lysis to measure CD4+T cell counts
using flow cytometry. We also inoculated some mice (n=3)
through rectal route. These mice were allowed to defecate before
rectal infection to prevent the immediate elimination of the virus.
Infections were performed in a volume of 75 ml (2500 TCID50) of
HIV-1Bal. Sterile 200 ml tips were preheated over a flame to
smoothen abrasive and sharp surfaces and were then used to
deliver the virus. Following delivery of the virus mice were kept in
an inverted position for 5 minutes to help virus adsorption in the
rectum.
Viral load Determination
Plasma viral RNA copy numbers were measured using cobas
ampliPrep/cobas TaqMan HIV-1 Test, version 2.0 (v2.0) (Roche,
Vilvoorde, Belgium). It is an in vitro nucleic acid amplification test
for the quantitation of HIV-1 RNA in plasma using the cobas
ampliPrep instrument for automated specimen processing and the
cobas TaqMan analyzer for automated amplification and detec-
tion. We processed five to seven samples in each group per time
point. Fifty microliters of murine plasma samples were diluted with
950 ml of assay diluent and processed with control seropositive and
seronegative human plasma samples. To determine proviral loads,
DNA was isolated using an extraction buffer (50 mM KCl,
10 mM Tris-HCl pH 8.3, 2.5 mM MgCl2, 0.5% Tween 20,
NP40 and Proteinase K). Earlier published HIV pol and gag gene
primers (Table 1) [16,17] were used to detect provirus in
peripheral blood of infected humanized mice by PCR. PCR was
carried out in a 100 ml reaction mixture containing 50 mM KCl,
10 mM Tris-HCL pH 8.3, 2.5 mM MgCl2, 0.2 mM dNTP, 2.5
units of Taq DNA polymerase (Roche, Vilvoorde, Belgium),
0.4 mM of each primer and 10 ng of DNA. First round of
amplification was performed with outer primers for 35 cycles, then
2 ml of the amplified DNA were amplified for 25 cycles with inner
primers. DNA from 8E5/LAV cells (NIH-AIDS Research and
Reference Reagent Program) was used as positive control.
Evaluation of Humoral Immune Responses
Concentrations of total human IgM and IgG in plasma of
humanized NSG mice were determined before and after HIV-1
infection by conventional human immunoglobulin quantification,
ELISA assay (Zeptometrix Cor., Buffalo, USA). HIV specific IgG
and IgM human antibodies were detected in the plasma sample
from HIV infected humanized mice by line immunoassay using
INNO-LIA
TM HIV I/II Score (Innogenetics NV, Ghent, Belgium)
according to the manufacturer’s instructions. Human positive and
negative controls were included with mice samples. 10 mlo f
sample was added to 1 ml sample diluent, test strips were
completely submerged in it and incubated overnight at room
temperature on a shaker. After washing three times in wash
solution, strips were incubated with the substrate solution, and the
reaction was stopped by stop solution. Results were interpreted
after the strips were dry.
Evaluation of Soluble Markers of Non-Specific Immune
Activation
b2-microglobulin levels were measured in mice plasma samples
before and after HIV-1 infection using an ELISA kit (Beckman
Coulter, Woerden, Netherlands). Lipopolysaccharide (LPS) levels
were also measured in mice plasma samples with standard ELISA
kits (Hyglos GmbH, Bernried, Germany and eBioscience,
Frankfurt, Germany).
Enzyme-Linked Immunosorbent Spot Assays
HIV-specific human T cells were identified in mononuclear cells
pooled from the lymph nodes and spleen of individual mice.
Enzyme-linked immunospot (ELISPOT) assayswere performed
using 2610
5 cells/well with peptide pool in 96-well polyvinylidene
plates (Millipore, Molsheim, France) pre-coated with capture anti–
human IFN-cmAb (Diaclone Besancon, France) and incubated at
4uC overnight. Next day cells were seeded in the presence of
proper stimulant (SEB or peptide pools). Plates were incubated
overnight at 37uCi n5 %C O 2 and developed according to the
manufacturer’s recommendations. Spots were counted using an
automated ELISPOT reader (Zeiss, Le Pecq, France). Peptide
pools consisting of 20 mers, with 10 amino acid overlaps and
spanning all expressed HIV proteins in the consensus clade B
sequences ofenvgp120s andgag p24, were obtained from the
National Institute for Biological Standards and Controls, United
Kingdom.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism
software. Data were expressed as the mean value 6 SD.
Significant differences between data groups were determined by
student t-test analysis. P value less than 0.05 was considered
significant.
Results
Human Immune Cell Reconstitution in NSG Mice
Previous protocols for humanization of NSG or NOG mice
required TBI before transplantation of CB-HPCs in order to
obtain sufficient CD45
+ human cell engraftment [5,6,7]. Alter-
native protocols using busulfan as a myelosuppressive agent in
neonate NSG mice have also been described [12,13,14,15].
Although busulfan indeed improves human CD45
+ cell engraft-
Table 1. Primers used for gag and pol gene DNA
identification in the peripheral blood of HIV-1 JRCSF infected
humanized NSG mice.
Region Primer code Sequences(59-39)
pol HPOL 4235* outer 59-CCCTACAATCCCCAAAGTCAAGG-39
HPOL 4538* outer 59-TACTGCCCCTTCACCTTTCCA-39
HPOL 4327* inner 59-TAAGACAGCAGTACAAATGGCAC-39
HPOL 4481* inner 59-GCTGTCCCTGTAATAACCG-39
gag HIV-gag1* outer59-
GCATTATCAGAAGGAGACCACCCCACAG-39
HIV-gag2* outer59-
TCCTGAACGGTACTAGTAGTTCCTGCTA-39
HIV-gag SK145* inner 59-GGTACATCAGGCCATATCACC-39
HIV-gag SK150* inner59-ACCGGTCTACATAGTCTC-39
doi:10.1371/journal.pone.0038491.t001
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the published protocols (i.e. need to transfer large numbers of
CB–CD34
+ cells, cost of cytokine treatment, difficulty of i.v.
injections in mice neonates and limited availability of human
fetal tissue) [12,14,15]. With the goal to improve busulfan-based
humanization protocols, we first treated a group of twenty 8–9
week old mice (group 1) with i.p. injection of busulfan 20 mg/kg,
24 hours prior to i.v.transplantation with 1610
5 frozen CB-
CD34
+ cells. We then evaluated engraftment levels by iterative
analysis of the blood of engrafted mice. We did not observe any
mortality with this dose of busulfan. Engraftment levels of human
CD45
+ cell at week 22 were 41.2665.70% (n=20) and stable
engraftment persisted up to 300 days (Fig. 1A and 1B).
We then sought to determine if changing transplantation
parameters could further improve engraftment of human CD45
+
cells. In a second group of twelve 8–9 week old mice (group 2),
busulfan was used at 30 mg/kg in combination with 1610
5 frozen
human CB-CD34
+ cells. This regimen allowed to reach engraft-
ment levels of 47.6164.10% (n=12), significantly better than with
busulfan 20 mg/kg (group 1) (P=0.0021). Decreasing the age of
mice to 5–7 weeks and using the same dosage of busulfan (30 mg/
kg) further improved the engraftment to 51.1366.13% (n=6)
(group 3), but this gain was not statistically significant in
comparison with group 2. Next, we increased the number of
transplanted CB-CD34
+ cells from 1610
5 to 2610
5. At the dosage
of 30 mg/kg busulfan (group 5), the engraftment was 64.4563.10
(n=7) and was very significantly better than with 1610
5 cells
(group 2) (P,0.0001) (Table 2). We also evaluated 100-cGy
irradiation and intrahepatic injection of 1610
5 CB-CD34
+ cells in
neonatal mice (n=10) (group 6), but observed 100% mortality
within seven days of transplantation.
Careful observation of the various protocols (Table 2) reveals
significant improvements of human CD45
+ cell engraftment by
increasing the dose of busulfan to 30 mg/kg (group 5) and using
2610
5freshCD34
+cells.Therefore,inordertofurtheroptimizethe
transplantation protocol, we concentrated on these parameters.
Neonatal mice classically show better engraftment compared to
adults but injecting them with HPCs is a delicate work. In contrast,
weaning and i.v. tail injection of 3–4 week old mice is an easier
procedure. Therefore, we chose this age group and used fresh
rather than frozen CB-CD34
+ cells. Hayakawa et al. reported good
tolerability of 50 mg/kg busulfan conditioning in NSG mice.
Hence we decided to administer two doses of busulfan 25 mg/kg
with a 12-hour interval. Under these conditions, the percentage of
human CD45
+ cells at week 22 was 91.9764.10% (n=20) and
mice survived up to 300 days (group 7) (Fig. 1A and 1B). This level
of engraftment was very significantly better than in group 5
(P,0.0001). We also measured white blood cell counts in the
blood of group 7 mice at 8 and 22 weeks after CB-CD34+ cell
transplantation. At 22 weeks, white blood cell count was 1885644
cells/ml for humanized mice and 64626285 cells/ml (n=4) in
human controls analyzed with the same settings (Fig. 1C). A
further increase in the busulfan dosage to 60 mg/kg caused
complete lethality (n=18) (group 8).
Transplantation of Fresh CB CD34
+ Cells Eesults in the
Differentiation of Major Human Leukocyte Lineages in
Blood and Lymphoid Organs
We next evaluated if the overall improvement of human cell
engraftment associated with group 7 protocol was observed in all
lymphoid sites and specifically correlated with a better or faster
differentiation of a given cell subset (i.e. CD19, CD3, CD4, CD8).
We compared engraftment achieved in groups 1 and 7, in blood,
spleen, lymph nodes and bone marrow at 12 and 22 weeks after
transplantation of CB-CD34
+ cells. At 22 weeks, high percentages
of human CD45
+ cells were observed in the lymph nodes
(95.5163.23%), bone marrow (83.4162.65%) and spleen
(74.3162.92%) (n=20) (Table 3). Humanized mice of group 7
also had higher absolute numbers of human cells in lymph nodes,
bone marrow and spleen compared with group 1 (Fig. 2A).
Twenty-four weeks after transplantation of fresh CB-CD34
+ cells,
lymph nodes of sizes from 3 to 7 mm could be observed in NSG
mice from group 7 (Fig. 2B).
In both groups, CD19
+ B cells were the major subset present at
week 12 (representing more than 80% of human CD45
+ cells) and
gradually declined afterwards. The decline of B cells was more
pronounced in group 7 in consistence with the T cell enrichment
associated with this protocol (Table 3 and Fig. 2C).
In accordance with these results, we found good proportions of
CD3
+ T cells in mice from group 7. At week 12, the percentage
of CD3
+ T cells was roughly three times higher in group 7 than
in group 1, all sites considered (Table 3 and Fig. 2C). Mesenteric
lymph nodes that were virtually absent in mice from group 1,
were well characterized in mice from group 7 and yielded a high
proportion of T cells (21.1563.90%, n=5). At week 22, the
percentage of CD3
+ T cells in the blood of mice from group 7
was 67.2964.88% (n=20) and remained significantly higher
compared to group 1 (35.6065.87%, n=20) (Table 3 and
Fig. 2C). Similar results were obtained for spleen and bone
marrow. Interestingly, engraftment was very good in thymus with
98.6361.23% human CD45
+ cells and 61.1064.91% (n=3)
human CD3
+ thymocytes. Among CD3
+ cells, 82.1363.43%
were CD4
+CD8
+ double positive and smaller proportions were
single positive CD4
+ (8.7162.13%) and CD8
+ (5.6163.21%)
cells (Fig. 2D). Among the CD3
+ T cell population of peripheral
blood of humanized mice 52.12611.11% (n=4) were CD45RO
and 46.43613.11% were CD45RA (n=4) (Fig. 2E).
Human monocytes, identified by the expression of human
CD14 were observed in the bone marrow (8.2263.16%) and
blood (2.3160.83%), 22 weeks after engraftment of mice from
group 7 (Fig. 2F). With the same protocol, human myeloid DCs
identified by the expression of CD11c were also present in the
spleen (3.1261.21%, n=6) (Fig. 2F).
Expression of HIV-1 Coreceptors
Next we studied the expression of HIV-1 co-receptors CXCR4
and CCR5 on human CD4
+ T cells in the lymphoid organs of
the humanized mice. CXCR4 was expressed on 78.11617.13%
(n=4) CD4
+ T cells in spleen and on 42.1614.1% (n=4) of
CD4
+ T cells in the lymph nodes (Fig. 3A). The proportion of
CD4
+ T cells positive for CCR5 was lower in both lymph nodes
6.5162.13% and spleen 7.1763.133%, indicative of a naı ¨ve
state of T cells (Fig. 3A). Large proportions of CD14
+ cells in the
bone marrow were also positive for CCR5 and CXCR4 (Fig. 3A).
Formation of Lymphoid Structures
After 22 weeks of CD34
+ cell transplantation in NSG mice, we
investigated the lymphoid structure formation and development
of human leukocytes, which is essential for elicitation of immune
responses against foreign antigens and the spread of HIV-1
infection. Immunohistochemical analysis of human CD45 leuko-
cytes showed that they gathered in a form of follicle-like
structures (FLSs) at the end of the central artery in the spleen.
In serial sections of the same region, these structures consisted
mainly of human CD20
+ B cells admixed with a small number of
human CD138
+ plasma cells. High levels of human CD45 cells
in lymph nodes were also confirmed by immunohistochemistry.
Labeling with CD3 and CD20 markers confirmed the presence
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of Ki-67 positive cells compared with the spleen, suggesting the
presence of high levels of actively proliferating cells. Also a high
percentage of human CD3
+ cells could be seen in the thymus of
engrafted mice (Fig. 3B).
TCR-Mediated Proliferative Responses of Human T Cells
Differentiated in a Murine Environment
Next, in order to prove that human T cells originating from
murine thymopoı ¨esis are indeed functional, we measured prolif-
erative responses induced by an antibody directed against human
CD3 in mononucleated cell suspensions prepared from murine
spleen and lymph nodes 22 weeks after transplantation of CB-
CD34
+ cells and compared them with those observed with PBMCs
from healthy donors. Although lower than in PBMCs, significant
proliferative responses were observed in cells isolated from both
murine lymphoid organs (Fig. 3C). The responses were higher in
lymph nodes than in spleen (Fig. 3C) especially when IL-2 rather
than anti-CD28 was used as a cosignal (Fig. 3C). Since the
proportion of human T cells differs between the different cell
Figure 1. Engraftment potential of CD34
+ hematopoietic cells. (A) Flow cytometric analysis of murine and human CD45
+ cells in the
peripheral blood of NSG mice of two different groups, representative profiles of the mice engraftment levels after 12 and 22 weeks after CD34
+ cells
transplantation. (B) Engraftment levels of human CD45
+ cells in peripheral blood up to 306 days after transplantation in group 1 and group 7. (C)
White blood cell counts at 12 and 22 weeks post-engraftment in group 7 mice along with human control.
doi:10.1371/journal.pone.0038491.g001
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interpret the differences observed but clearly rules out a global
anergy of T cells recovered from humanized mice.
Sustained, High-Level of HIV-1 Replication in Humanized
NSG Mice
Humanized mice were inoculated i.v. with two different HIV-1
isolates. We usedCCR5-tropic (R5-tropic) JRCSF and HIV-1Bal
isolates inoculated at 10,000 TCID50 doses for infection. Mice
were bled at 20, 40, 60, 80, 100 and 120 days postinfection and
plasma viral loads were determined by cobas AmpliPrep/cobas
Taq Man Version 2.0 HIV-1 assay. Productive infection was
observed after inoculation with both isolates. For HIV-1Bal, viral
load reached 4.2610
562.2610
5 copies/ml on day 40 and
remained over 1.9610
565.8610
4 copies/ml at the three following
time points. Viral loads were lower for HIV-1JRCSF reaching
1.6610
563.5610
4 copies/ml at day 60 and 1.85610
563.2610
4
copies/ml 100 days after infection. Viral loads were still detected
at day 120 for both isolates (Fig. 4A). In a preliminary experiment,
mice infected by the rectal route (BAL isolate at 2500 TCID50)
and showed high levels of plasma viral load 0.93610
562.2610
4
copies/ml (n=3) 35 days after inoculation.
We confirmed the presence of HIV in the peripheral lymphoid
tissues of humanized infected mice by immunohistochemical
staining of HIV gag-p24 antigen. Infection was distributed
primarily in the T cell rich periarteriolar lymphoid sheaths of
the spleen and was more diffuse in the lymph nodes of humanized
mice (Fig. 4B). A necropsic section of the lymph node of a 39 year
old patient deceased of AIDS in 1990 was provided by the Lie `ge
Biobank (Ethical agreement 2010/29) and stained for gag p24 as a
positive control. Detection of proviral DNA was also performed to
in these humanized NSG mice. We isolated DNA from circulating
peripheral blood of mice nine weeks postinfection and performed
gag and pol gene PCR. We could detect provirus in five mice out of
nine. Three mice were positive for gag and two were positive for pol
(Fig. 4B). We could not detect proviral load in all the samples
either because of PCR failure or peripheral blood cells might have
lower levels of proviral DNA.
HIV-1 Infection Progression in Infected Humanized NSG
Mice
Infections with both HIV-1JRCSF and HIV-1Bal isolates were
associated with depletion of CD4
+ T cells in the blood of
humanized NSG mice. Decline in CD4
+ T cell percentage could
already be seen at 25 days after infection and continued until 120
days postinfection (4 to 6 mice each timepoint) (Fig. 4D and 4E).
We have measured total numbers of circulating lymphocytes at
nine time points in three HIV-Bal infected humanized mice to
determine the absolute numbers of CD4
+ T cells. The absolute
CD4
+ cell count decreased significantly to the same extent as the
percentage CD4
+ T cells declined. Before infection three infected
mice had average CD4 count of 672696.08 cells/ml, but it
decreased significantly (493.33672.34 and 358.66 cells/ml) 25 and
50 days after infection. However, because of restriction of sample
volume to perform dual platform method analysis (hematological
analyzer and flow cytometry), determination of absolute CD4
+ cell
count could not be performed at all-time points.
Immune Activation, Exhaustion and Senescence after
Infection of Humanized NSG Mice with HIV-1JRCSF
Aspecific activation of the innate immune system has been
described in HIV-1 infection and possibly drives subsequent
activation of the adaptive immune response. Levels of non-specific
immune activation marker such as b2-microglobulin have been
correlated with disease progression [18]. In humanized mice, HIV
infection induced a strong increase of b2-microglobulin from
0.4260.09 mg/l at day 0 to 5.4160.29 mg/l (n=4). Aging in
non-infected mice was associated with a moderate increase of b2-
microglobulin but this marker remained much lower than in the
infected animals (Fig. 5A). Next we studied the expression of early
activation markers CD69 and HLA-DR on CD4 and CD8 T cells
of humanized mice after HIV infection. The percentage of CD4
+
T cells expressing CD69 increased from 0.6760.29% to
4.5561.58% (n=4) whereas it went from 0.3060.21% to
8.3361.38% (n=4) for CD8
+ T cells (Fig. 5B). The increase in
HLA-DR expression after HIV infection was even more
pronounced. The expression of HLA-DR was observed on
2.5060.81% of CD4
+ T cells and 3.0060.80% of CD8
+ T cells
before infection and jumped to 39.2862.90% (n=4) and
49.9862.24% (n=4) respectively for CD4
+ and CD8
+ T cells
after infection (Fig. 5C). Some activation markers are specifically
linked to impaired T cells functions. This is the case for the
inhibitory receptor PD-1 (Programmed Death 1), which is a
marker for T cell exhaustion [19]. After infection with HIV-
JRCSF, there was a strong increase of the percentage of T cells
positive for PD-1 in comparison with non-infected counterparts.
This was true for CD4
+ (16.5061.84% (n=4) vs. 1.2960.89%
(n=4)) as well as for CD8
+ T cells (22.2561.37% (n=4) vs.
2.5962.34% (n=4)) (Fig. 5D). CD27, a receptor involved in co-
stimulation, is down regulated with advancing cell differentiation
from early-differentiated CD27
+ memory T cells to late differen-
tiated CD27
2 memory T cells. The loss of CD27 on T cells is
classically viewed as marker of immune senescence and occurs in
HIV infection. In HIV-infected NSG humanized mice, we
observed down-regulation of CD27 expression in CD4
+ (from
Table 2. Transplantation conditions and engraftment levels of human CD45
+ cells after 22 weeks in various groups of NSG mice.
Group Number Age of mice Busulfan dose CB-HSCs CD45 Engraftment %
Group 1, n=20
Group 2, n=12
Group 3, n=6
Group 4, n=6
Group 5, n=7
Group 6, n=10
Group 7, n=20
Group 8, n=18
8–9 weeks
8–9 weeks
5–7 weeks
8–9 weeks
8–9 weeks
5–7 days
3–4 weeks
3–4 weeks
20 mg/kg
30 mg/kg
30 mg/kg
20 mg/kg
30 mg/kg
TBI-100cGy
25–25 mg/kg
(split dose)
30–30 mg/kg
(split dose)
Frozen21610
5
Frozen21610
5
Frozen21610
5
Frozen22610
5
Fresh22610
5
Frozen21610
5
Fresh22610
5
Fresh22610
5
41.2665.70%
47.6164.10%
51.1366.13%,
48.3365.13%,
64.4563.10%
2
91.9764.10%
2
doi:10.1371/journal.pone.0038491.t002
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and CD8
+ T cells (from 91.2561.89% to 77.5063.11%) (Fig. 5E).
Activation of CD4
+ T cells is also associated with upregulation
of CCR5 and may therefore render T cells more susceptible to
infection. In non-infected humanized mice, only 1.6760.39% of
CD4
+ T cells and 1.5760.86% of CD8
+ T cells were positive for
CCR5. Six weeks after infection, 26.2363.05% of CD4
+ T cells
and 30.0364.43% of CD8
+ T cells expressed the HIV coreceptor
(Fig. 5F). Microbial translocation has recently been proposed to
play a central role in chronic inflammation and subsequent
activation of adaptive immunity in HIV-infected individuals [20].
We have measured LPS levels in plasma of HIV-1 infected mice 2
and 8 weeks after infection. At 2 weeks, LPS levels were
0.0660.02 EU/ml, which increased significantly to
6.6260.68 EU/ml at 8 weeks after infection (Fig. 5G). LPS was
below detection limits in non-infected humanized mice.
Humoral Immune Responses in HIV Infected Humanized
NSG Mice
To determine whether B cells are functionally mature and can
differentiate into plasmocytes and secrete immunoglobulins after
HIV-1 infection, we measured levels of total human IgG and IgM
and specific antibodies in humanized mice. Before HIV infection,
humanized mice produced low but detectable amounts of IgG
0.1360.01 mg/ml, n=6 and IgM 2.2260.13 mg/ml, n=6.
Interestingly, IgG increased significantly after HIV-1 infection
and reached 1.6960.53 mg/ml, n=6 (Fig. 6A). Conversely, there
was a modest decrease of the IgM levels at 2.1660.04 mg/ml,
n=6 (Fig. 6B).
We next tested the infected humanized mice for the presence of
human antibodies directed against HIV-1, using line immunoas-
say. Antibody reactions to the HIV antigen bands gp120, gp41,
p31, p24, p17 of HIV-1 and gp105 and gp36 of HIV-2 were
assessed using INNO-LIA test strips. Six weeks after infection, all
mice were negative for anti-HIV-1 specific antibodies. At week 9,
3 mice of out 12 displayed reactivity towards four antigen bands
and 2 mice had a weaker response directed against one antigen
band only (Fig. 6C).
Cell-Mediated Immune Responses Directed Against HIV
in Infected Humanized NSG Mice
We also evaluated the generation of specific cellular immune
responses directed against HIV antigens. CD8
+ T cells secreting
granzyme B and perforin are critical for efficient cytolytic function.
Therefore, we evaluated the presence of these cytotoxic com-
pounds in the CD8
+ T cells of infected mice using intra-
cytoplasmic staining and flow cytometry. We noted a significant
increase in the expression levels of both molecules in CD8
+ T cells
six weeks after HIV-1 infection. The percentage of CD8
+ cells
expressing granzyme B increased from 1.6560.18% (n=4) to
Figure 2. Human cell differentiation in humanized NSG mice. (A) Absolute number of human cells in lymph nodes, bone marrow and spleens
of group 1 and group 7 mice. (B) Mesenteric and brachial lymph nodes from male mice obtained after 24 weeks of CD34
+ cell transplantation in
group 7 mice. (C) Flow cytometric analysis of engraftment percentage of CD3
+ T cells and CD19
+ B cells at 12 and 22 weeks after transplantation of
CD34
+ cells in representative mice from group 1 and group 7. (D) Flow cytometric analysis of CD4
+CD8
+, CD4
+ and CD8
+ population in thymus of 22
weeks engrafted mice. (E) Flow cytometric analysis of CD45RA
+ and CD45RO
+ positive CD3 cells 22 weeks after engraftment in mice from group 7. (F)
Representative profile CD11c
+ cells in spleen and CD14
+ population in bone marrow and blood of group 7 mice 22 weeks after CD34
+ cell
transplantation.
doi:10.1371/journal.pone.0038491.g002
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percentage increased from 1.660.13% (n=4) to 24.5360.81%
(n=4) for perforin (Fig. 7B). Levels of granzyme B and perforin
remained unchanged in CD4
+ T cells (Fig. 7A and 7B).
Next, we performed an IFN-c-based ELISPOT assay to
measure anti-HIV responses in humanized mice nine weeks after
infection (n=5). Mononucleated cells from spleen and lymph
nodes of five infected mice were activated with SEB (0.5 mg/ml) as
a positive control or with a pool of overlapping peptides for gag and
env (Fig. 7C and 7D). A significant response was observed in 3 out
of 5 mice, especially in mouse 1 where 200613 spot forming cells/
10
6 were counted for gag and 150615 for env. Overall responses
against gag were higher than against env in all mice. Two
noninfected mice were also tested, and no detectable ELISPOT
responses to HIV peptides could be observed (Fig. 7C and 7D).
Discussion
Development of a long lasting fully functional human immune
compartment in immunodeficient mice is a prerequisite for in vivo
HIV-1 studies [1]. We have developed a practical humanized
mouse model that allows, in a reproducible fashion, high levels of
human cell engraftment suitable for HIV-1 studies. In our final
protocol, we performed conditioning of mice with busulfan at
50 mg/kg administered in two split doses and transplanted fresh
CB-CD34
+ cells in 3–4 week old mice. Our strategy resulted in
92% of human CD45
+ cell chimerism in the peripheral blood of
humanized mice.
We observed significantly higher engraftment levels of human
CD45
+ cells in comparison with previous studies with busulfan-
conditioned and CB-CD34
+ transplanted mice. Hayakawa et al.
have reported 61% human cell chimerism in humanized mice
after 50 mg/kg busulfan preconditioning and transplantation of a
high number of CB-CD34
+ cells (2610
6) in 8–12 weeks old mice
[12]. Kim et al. transplanted CD34
+ cells along with fetal thymus/
liver/bone tissue and observed 31% engraftment of human
CD45
+ cells in peripheral blood of humanized mice. These
neonate mice were conditioned with 15 mg/kg busulfan dose.
Choi et al. have also reported use of 20, 30, and 40 mg/kg busulfan
dose for transplantation of CD34
+ cells in 6-week old NSG mice.
However, observed levels of engraftment were lower in these mice
compared to our study (Table 4).
We believe that a unique combination of several factors is likely
to explain our good engraftment levels. We were able to use a
relatively high dose of busulfan (50 mg/kg) without inducing
mortality thanks to the split dose regimen advocated by previous
authors [12]. We also used HPCs immediately after their
processing by the cord blood bank and without cryopreservation.
Unfortunately, our experiments were not set up to discriminate
between the respective effect of busulfan dosage on the one hand
and using fresh HPCs on the other. Nevertheless, we believe that
using HPCs without cryopreservation might be an important
factor since previous reports have suggested that cryopreserved-
thawed HPCs contain significant proportions of apoptotic cells
that do not contribute in engraftment and cannot be detected by
regular viability dyes [21]. It is also known that cryopreservation of
CD34
+ cells reduces expression of cell adhesion/homing molecules
such as L-selectin (CD62L) which play a major role in the
migration of transplanted cells [22]. Further experiments are
required to evaluate with more accuracy the importance of this
factor in our model.
It is also known that the age of the mice has a significant
influence on the engraftment levels of human CD45
+ cells [8]. We
Figure 3. Coreceptor expression and lymphoid organ forma-
tion in humanized mice. (A) Representative FACS profile of human
CCR5
+CD4
+ and CXCR4
+CD4
+ cells in spleen and lymph nodes, gate was
set of human CD45 cells. Expression of CCR5 and CXCR4 were checked
on CD14
+ cells, gate was set on live human cell population. (B)
Histology of lymphoid organs in CD34
+ engrafted NSG mice. The
lymphoid follicles mainly contained hCD45 cells. Spleen sections were
stained with (a) anti-hCD45, (b) anti-hCD20 and (c) anti-hCD138. Lymph
node sections were also stained with (d) anti-hCD45, (e) anti-hCD20 (f)
anti-hCD3 (g,h) anti-hKi67 antibodies. Thymus section was stained with
anti-CD3 antibody. (C) Proliferative responses of T cells were measured
in nonstimulated cells, after stimulation with immobilized anti-CD3/
anti-CD28 and anti-CD3+IL2 in spleen (white bars), lymph nodes (gray
bars) and human PBMCs (black bars).
doi:10.1371/journal.pone.0038491.g003
New Protocol for an Efficient HIV Mouse Model
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38491therefore chose to use 3–4 week-old mice, which are furthermore
easier to manipulate, compared to neonates.
Another practical advantage of this protocol is the relatively low
number of fresh CD34
+ cells needed to get optimal reconstitution.
In comparison with Hayakawa et al. we used ten times less CD34
+
cells to achieve high levels of human CD45
+ cell engraftment. This
allows to engraft more mice with a single cord blood and therefore
to limit interdonor variability in functional studies.
Figure 4. Sustained high-level of HIV dissemination and infection progression. (A) Humanized mice were i.v. injected with HIV-1 JRCSF and
HIV-1 Bal at 10,000 TCID. Mice were bled at 20, 40, 60, 80, 100 and 120 days to detect plasma viral load, curve represent the viral load at different time
point. Error bars (B) Sections of lymph node (a) and spleen (b) of humanized HIV infected mice were stained using anti-p24 antibody. Brown color
show p24 specific staining. Lymph node of HIV-1 infected human (c) is shown as positive control and engrafted noninfected mouse spleen (d) is
shown as negative control. (C) DNA was extracted from peripheral blood of HIV-1JRCSF-infected mice 9 week after infection. Determination of HIV-1
DNA copy was performed by PCR assay for gag and pol gene. 8E5 cell DNA was amplified as positive control (PC) along with humanized mice DNA
(hm1, hm2, and hm3) (D, E) Percentage of CD4
+ cells of T-cells following HIV-1 infection, each circle represent one mouse infected with HIV-1 JRCSF
and each square represent one mouse infected with HIV-1 Bal means of CD4% of CD3
+ cells at time point of infection are shown in solid line.
doi:10.1371/journal.pone.0038491.g004
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38491Figure 5. HIV induced immune activation and expression levels of multiple activation markers on CD4
+ and CD8
+. Blood samples were
obtained from mice before and 6 week after HIV-1 JRCSF infection. (A) Beta-2-microglobline levels were measured using ELISA before (Pre) and after
HIV-infection (Post) (n=4) and at same time intervals in engrafted but noninfected mice. (B) CD69 (C) HLA-DR (D) PD-1 and (E) CD27 (F) CCR5 levels
New Protocol for an Efficient HIV Mouse Model
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38491The good results obtained at 12 weeks were confirmed at
further time points and at different sites including bone marrow,
spleen and lymph nodes. Few published reports have described the
development of visible lymph nodes in humanized immunodefi-
cient mice [23,24]. Interestingly, we observe several mesenteric
lymph nodes in all our reconstituted mice with sizes ranging from
3 to 7 mm size. We were even able to detect axillary lymph nodes
in some engrafted animals.
Importantly, the overall improvement of engraftment levels was
associated with the preferential expansion of T cells in these mice
(Table 3). Once again, this might be related to the age of the mice
used in our experiments. Previous reports have shown differences
were evaluated on CD4
+ and CD8
+ cells. (G) LPS levels in humanized mice 2 and 8 weeks post-HIV infection. Each circle and square represent one
mouse at the indicated time point. Means are shown in solid lines. P values were determined by unpaired student’s t-tests. ** indicates a
P value,0.001 and *** indicates a P value,0.0001.
doi:10.1371/journal.pone.0038491.g005
Figure 6. Humoral immune responses in HIV infected humanized NSG mice. (A, B) Detection of IgG and IgM level in the plasma of 6 mice
before HIV infection (Pre-closed circle) and 6 weeks after HIV-1 JRCSF infection (Post-closed square) by ELISA assay. Each circle represents one mouse;
means are shown in solid lines. P values were determined by unpaired student’s t-tests. *** indicates a P value,0.0001. (C) Line immunoassay was
used to determine HIV-1 specific human antibodies in HIV-1 JRCSF infected mice (n=12). Nine weeks after infection positive (n=3) and equivocal
(n=2) anti-HIV-1 specific human antibodies response could be seen. Positive and negative human controls are shown for comparison.
doi:10.1371/journal.pone.0038491.g006
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e38491Figure 7. T-cells cellular immune responses to HIV infection. (A, B) Expression of cytotoxic effector molecules perforin and granzyme B are
measured by flow cytometry before and 6 weeks after HIV-1 infection in humanized NSG mice (n=4). Means are shown in solid lines and P values
were determined by paired student’s t-tests, are shown for significant statistical comparisons. (C) ELISPOT assay measured IFN-c secretion from
mononuclear cells, pooled from lymph nodes and spleen and stimulated with HIV-1 gag or env peptides. In left panel of engrafted but noninfected
mice, non-specific stimulation with SEB lead to generation of response and no IFN- c secreting cells could be detected after HIV-1 peptide
stimulation. In the middle and right panels of HIV infected mice, IFN-c responses were seen with nonspecific stimulation with SEB but also when
stimulated with HIV-1 peptide. HIV-1 Gag peptides stimulation responses were higher than HIV-1 env peptides in all infected mice. (D) Quantification
of IFN-c secreting HIV-1-specific T cells in an HIV-1-infected humanized mice detected by an ELISPOT assay. Pools of peptides spanning all of gag and
env were used for overnight stimulation. Each spot represent IFN-c secreting cell. The frequency of responses is depicted as IFN-c spot-forming cells
per 10
6 cells.
doi:10.1371/journal.pone.0038491.g007
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immunodeficient mice [8,23]. The thymus hypoplastic cysts,
which increase with age, make the thymic microenvironment
unsuitable for the development of human prothymocytes.
A previous study in NOG mice suggested that, although human
T cells have a normal phenotype, they are neither abletoproliferate
nor to produce IL-2 in response to stimulation by anti-CD3/anti-
CD28 antibodies [10]. The authors postulated that this abnormal
function could be related to the involvement of murine MHC
expressed on thymic epithelium in the selection of human T cells.
In our experiments, after 22 weeks of engraftment, we did not
observe such an anergy since human cells isolated from the lymph
nodes responded satisfactorily to T cell stimulation. Interestingly,
the responses were lower in the spleen than in the lymph nodes.
This could be due to a lower proportion of T cells in this organ but
also to anergic state of splenic T cells due to chronic response
directed against HLA class II expressed by B cells as suggested by
Watanabe et al. [10].
After intravenous inoculation of humanized NSG mice with
HIV-1Bal and HIV-1JRCSF isolates, we observed high levels of
viral replication and a rapid decline of CD4
+ T cell counts.
Further experiments will be needed to determine if our model
can sustain the viral replication beyond 120 day despite dramatic
CD4 lymphopenia. It has indeed been previously reported that
Rag2
2/2cc
2/2 mice conditioned with TBI and transplanted
with human CD34
+ cells sustain high-titer infection persisting
more than one year and associated with a slower decline of CD4
T cells after inoculation of an R5 strain [25,26]. The reasons for
different paces of CD4
+ T cell depletion in both models are
unknown.
We have observed an upregulation of various membrane
markers associated with immune activation, senescence and
exhaustion on the CD4
+ and CD8
+ T cells of our infected
humanized mice. Similar findings have been previously reported
with the humanized BLT-NSG mice [27,28] and with Rag2
2/
2cc
2/2 mice transplanted with HPCs [29] confirming that
immune activation is a robust and cardinal feature of HIV
infection in different settings. Interestingly, we were the first to
describe in a murine model the dramatic increase of b2-
microglobulin associated with the progression to human AIDS.
Bacterial translocation of microbial products has been proposed
to be a major cause for immune activation in HIV infection.
After HIV infection of our HPCs transplanted humanized NSG
mice, we indeed observed elevated plasma LPS levels. Hofer et al.
recently reported similar findings in Rag2
2/2cc
2/2 mice [29].
Interestingly, our study showed plasma LPS below detection
levels in non-infected humanized mice. This very low baseline of
plasma LPS, crucial for further studies, might be related to our
conditioning protocol since TBI conditioning is known to
increase LPS levels in mice [30].
Modest but significant anti-HIV specific humoral immune
responses could be detected after 9 weeks of infection in three
mice. This could be due in part to an intrinsic defect of humoral
responses in such murine models. Despite an increase of total IgG
in the infected animals, these levels remained very low in
comparison to what is observed in humans. This defect is likely
to be due to the murine environment, which does not provide the
critical growth factors necessary for proper B cells maturation and
homeostasis [31]. This hypothesis is supported by our observation
of a lower number of CD138
+ immunoglobulin secreting plasma
cells in the spleen. Choi et al. have reported that NSG mice
engrafted after a dose of 30 mg/kg of busulfan have a better B cell
development, which includes memory B cells than after condi-
tioning with TBI or with a lower dose of busulfan [13]. Thus, it is
possible that our conditioning protocol with busulfan at 50 mg/kg
has probably contributed to the development of the modest anti-
HIV-1 humoral responses seen in our humanized mice. Further
improvement in B cell response could be achieved with treatment
of the humanized NSG mice with B lymphocyte stimulator (BlyS/
BAFF) to humanized NSG [31].
The high expression levels of perforin and granzyme B in CD8
+
T cell suggests that these cells are functional and could play a role
in control of HIV infection in humanized mice. The moderate
number of IFN-c secreting cells in our ELISPOT test further
shows the presence of specific T cell responses against HIV
antigens. However, T cells sorting and the use of lymph nodes
rather than spleens as they have higher percentage of T cells, could
allow the detection of the rare anti-HIV antigen specific T cells in
humanized NSG mice.
Although our protocol is easy, efficient and reproducible, we
fear that the need for HPCs obtained either fresh or cryopreserved
in optimal conditions could impact its performance in some
research settings. In previous publications of the Rag22/2cc2/
2 mouse model (RAG-hu), human fetal liver-derived CD34
+ cells
were cultured for 1-day in cytokine media containing IL-3, IL-6
and SCF 2 and injected into neonatal mice after irradiation at 350
rads, intrahepatically [32]. These RAG humanized mice are
productively infected by HIV-1. They produced continued long-
term infection with X4-tropic or R5- tropic HIV-1 and have been
evaluated for effective HIV-1 mucosal transmission [33]. Potential
of similar protocol with busulfan conditioning and use of human
cytokines pre-treated fetal liver derived CD34
+ cells for transplan-
Table 4. Comparison of published busulfan-preconditioning protocols, kind and number of CD34
+ cells transplanted and
engraftment levels of human CD45
+ cells in peripheral blood (PB), spleen and bone marrow (BM) of NSG mice.
Busulfan dose Age of mice Injection route Number of cells
Engrafted
tissue CD45 cells percentage Publication
PB Spleen BM
15 mg/kg Newborn Intrahepatic CB–CD34
+,2 610
5 2 ,41% ,61% ,71% Choi et al. 2011 Clinical immunology
15 mg/kg Newborn Intrahepatic FL–CD34
+,2 610
5 Fetal
thymus/
bone
,31% 79% 84% Kim et al. 2011 Journal of clinical
immunology
30 mg/kg 6–8 week Tail vein CB–CD34
+,1 610
5 2 62% 80% 45% Choi et al. 2011 Journal of clinical
immunology
50 mg/kg as (25–25)
mg/kg
7–10 week Tail vein CB–CD34
+,2 610
6 2 61% 22 Hayakawa et al. 2009 Stem cells
doi:10.1371/journal.pone.0038491.t004
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of fresh CD34
+ cell is a limitation to achieve high engraftment
levels.
Our new protocol of HPCs transplantation induces efficient
engraftment in NSG mice. It not only improves the level and
function of T cells and lymphoid organogenesis, but it also mimics
HIV-1 replication, immune activation and pathogenesis mecha-
nism as observed in human. However, generation of moderate
anti-HIV specific IgG responses and CTL responses support the
need for further improvement in CB-34
+ cell transplanted
humanized NSG mouse model.
Better anti-EBV CTL responses have been observed in
newborn NSG-HLA-A2/HHD mice compared with NSG mice
[34]. We have also started evaluating the same engraftment
protocol described in this manuscript for future use in NSG-HLA-
A2/HHD mice. Our preliminary results with NSG-HLA-A2/
HHD mice suggest that our protocol of 50 mg/kg with two split
doses of 25 mg/kg in 3–4 week old mice is well tolerated and able
to produce high levels of engraftment in these mice as well. Thus,
the protocol delineated in this article could be used with NSG-
HLA-A2/HHD mice. This would be interesting since humanized
NSG-HLA-A2/HHD mice have been shown to elicit strong T cell
responses directed against HLA-A2-restricted dengue virus and
EBV peptide [34,35].
In summary, we have shown that high levels of human cell
chimerism can be created in humanized NSG mice without the
use of TBI. These mice can provide a valuable model to
investigate HIV pathogenesis and immune activation mechanism
and host immunity in vivo along with an opportunity to evaluate
new therapeutic strategies.
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